Single Technology Appraisals in Scotland

Below are the NICE STA alerts issued by Healthcare Improvement Scotland and our predecessor NHS Quality Improvement Scotland.

STA guidance is not applicable to NHSScotland and alerts are provided for information only. NHSScotland should follow advice issued by the Scottish Medicines Consortium on new medicines.

NICE STA Guidance no 282 - Idiopathic pulmonary fibrosis - pirfenidone
NICE STA guidance no 280 - Rheumatoid arthritis (2nd line) - abatacept (rapid review of TA 234)
NICE STA Guidance 277 - Methylnaltrexone (Terminated Appraisal)
NICE STA guidance 275 - Apixaban for preventing stroke and systemic embolism
NICE STA Guidance No 255 – Cabazitaxel for hormone-refractory metastatic prostate cancer
NICE STA Guidance 272 - Vinflunine for advanced or metastatic transitional cell carcinoma of the urothelial tract
NICE STA 274 Ranibizumab for the treatment of diabetic macular oedema (rapid review of TA237)
NICE STA Guidance no 269 Vemurafenib for advanced or metastatic BRAF V600 mutation-positive malignant melanoma
NICE STA guidance 273 Hyperplasia (benign prostatic) – tadalafil (terminated appraisal)
NICE STA guidance 271 - Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema
NICE STA guidance no 281 - Canakinumab for gout – terminated appraisal
NICE STA Guidance no 267 – ivabradine for treating chronic heart failure
NICE STA Guidance No 264 – Alteplase for treating acute ischaemic stroke
NICE STA Guidance No 270 – Leukaemia (acute myeloid ) – decitabine (terminated appraisal)
NICE STA Guidance 263 - Bevacizumab in combination with capecitabine for metastatic breast cancer
NICE STA Guidance no 268 - Ipililmumab for previously treated advanced (unresectable or metastatic) melanoma
NICE STA Guidance No 266 - mannitol dry powder for inhalation for treating cystic fibrosis
NICE STA Guidance 262 – Adalimumab for the treatment of moderate to severe ulcerative colitis
NICE STA Guidance No 259 – Abiraterone for castration-resistant metastatic prostate cancer
NICE STA Guidance No 256 Rivaroxaban - prevention of stroke and systemic embolism in people with atrial fibrillallation
NICE STA Guidance No 258 – Erlotinib for EGFR-TK mutation-positive non-small-cell lung cancer
NICE STA Guidance 261 – Rivaroxaban for the treatment of deep vein thrombosis
NICE STA Guidance No 260 – Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
NICE STA Guidance no 253 - Boceprevir for the treatment of genotype 1 chronic hepatitis C
STA 236 – Ticagrelor for the treatment of acute coronary syndromes
NICE STA Guidance No 248 – Exenatide prolonged-release suspension for injection
NICE STA Guidance no 252 - Telaprevir for the treatment of genotype 1 chronic hepatitis C
NICE STA Guidance 250 - Eribulin for the treatment of locally advanced or metastatic breast cancer
NICE STA Guidance No 247 – Tocilizumab for the treatment of rheumatoid arthritis
NICE STA Guidance No 249 Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
Nice STA Guidance No. 245 – Apixaban for the prevention of venous thromboembolism
STA Guidance No 239 – Fulvestrant for the treatment of locally advanced or metastatic breast cancer
NICE STA guidance 244 - Roflumilast for the management of severe chronic obstructive pulmonary disease
NICE STA Guidance No 254 - Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis
STA Guidance No 240 – Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer
Appraisal Guidance No 232 – Retigabine for the adjunctive treatment of partial onset seizures in epilepsy
Appraisal Guidance No 230 – Bivalirudin for the treatment of ST-segment-elevation myocardial infarction
STA 235 - Mifamurtide for the treatment of osteosarcoma
Appraisal Guidance No 234 – abatacept for the treatment of rheumatoid arthritis
Appraisal Guidance No 233 – golimumab for the treatment of ankylosing spondylitis
STA Guidance No 238 – Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
Appraisal Guidance No 227 – Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
Appraisal Guidance No 229 – Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal
NICE Single Technology Appraisal Guidance No 220 Golimumab for the treatment of psoriatic arthritis
Appraisal Guidance No 226 – Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma
Appraisal Guidance No 225
Technology Appraisal Guidance No 221 – Romiplostim for the treatment of thrombocytopenic purpura
Appraisal Guidance No 219 – Everolimus for the second-line treatment of advanced renal cell carcinoma
Appraisal Guidance No 222 – Trabectedin for the treatment of relapsed ovarian cancer
Appraisal 218 Azacitidine 23rd March 2011
Appraisal Guidance No 191 – Capecitabine for the treatment of advanced gastric cancer
Appraisal Guidance No 215 – Pazopanib for the first-line treatment of advanced renal cell carcinoma
Appraisal Guidance No 208 – Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
Appraisal Guidance No 216 – Bendamustine for the first-line treatment of chronic lymphocytic leukaemia
Appraisal Guidance No 213 – Aripiprazole for the treatment of schizophrenia in people aged 15-17
NICE STA Guidance No 237 – Ranibizumab for the treatment of diabetic macular oedema
Appraisal Guidance No 202 Ofatumumab for the treatment of refractory chronic lymphocytic leukaemia
Appraisal Guidance No 211 – Prucalopride for the treatment of chronic constipation in women
Appraisal Guidance No 207 – Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated ap
Appraisal Guidance No 206 – Bendamustine for the treatment of indolent (low grade) non-Hodgkin’s lymphoma that is refrac
Appraisal Guidance No 201 Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11
Apprasial Guidance No 203 Liraglutide for the treatment of type II diabetes mellitus
Appraisal Guidance No 196 – Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Appraisal Guidance no. 205 Eltrombopag for treatment of thrombocytopenic purpura
Appraisal Guidance No. 204 Denosumab for the prevention of osteoporotic fractures
Appraisal Guidance No 197 – Dronedarone for the treatment of non-permanent atrial fibrillation
Appraisal 214 Bevacizumab 23rd March 2011
Appraisal Guidance No 198 – Tocilizumab for the treatment of rheumatoid arthritis
Appraisal Guidance No 193 – Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
Appraisal Guidance No 192 – Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lun
Appraisal Guidance No 180 – Ustekinumab for the treatment of adults withmoderate to severe psoriasis
Appraisal Guidance 182 – Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention
Appraisal Guidance No 186 – Certolizumab pegol for the treatment of rheumatoid arthritis
Appraisal Guidance No194 – Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer
Appraisal Guidance No 185 – Trabectedin for the treatment of advanced soft tissue sarcoma
Appraisal Guidance No 176 – Cetuximab for the first-line treatment of metastatic colorectal cancer
Appraisal Guidance No 189 – Sorafenib for the treatment of advanced hepatocellular carcinoma
Appraisal Guidance No 179 – Sunitinib for the treatment of gastrointestinal stromal tumours
Single Technology Appraisal Guidance No 190 – Pemetrexed for the maintenance treatment of non-small-cell lung cancer
Appraisal Guidance No 183 – Topotecan for the treatment of recurrent and stage IVB cervical cancer
Appraisal Guidance No 129: Bortezomib monotherapy for relapsed multiple myeloma
Appraisal Guidance No 144 Rimonabant for the treatment of overweight and obese adults
Appraisal Guidance 175 – Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung c
Appraisal Guidance No 157- Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replaceme
Appraisal Guidance No 146 Adalimumab for the treatment of adults with psoriasis
Appraisal Guidance No 153 - Entecavir for the treatment of chronic hepatitis B
Appraisal Guidance No TA172 – Cetuximab for the treatment of recurrent andor metastatic squamous cell cancer of the he
Appraisal Guidance No170 – Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replac
Appraisal Guidance No 171 – Lenalidomide for the treatment of multiple myeloma in people who have received at least one
Appraisal Guidance No 163 – Infliximab for acute exacerbations of ulcerative colitis
Appraisal Guidance No 145 – Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Appraisal Guidance No 174 – Rituximab for the first-line treatment of chronic lymphocytic leukaemia
Appraisal Guidance No162 – Erlotinib for the treatment of non-small cell lung cancer
Appraisal Guidance No 141 – Abatacept for the treatment of rheumatoid arthritis
Appraisal Guidance No 173 – Tenofovir disoproxil for the treatment of chronic hepatitis B
Appraisal Guidance No 177 – Alitretinoin for the treatment of severe chronic hand eczema
Appraisal Guidance No 164 – Febuxostat for the management of hyperuricaemia in people with gout
Appraisal Guidance No 113 - Inhaled Insulin for the Treatment of Diabetes (Types 1 and 2)
Appraisal Guidance No 134 Infliximab for the treatment of adults with psoriasis
Appraisal Guidance No 122: Alteplase for the treatment of acute ischaemic stroke
Appraisal Guidance No 124: Pemetrexed for the treatment of non-small cell lung cancer
Appraisal Guidance 125: Adalimumab for the treatment of psoriatic arthritis
Appraisal Guidance No 154 - Telbivudine for the treatment of chronic hepatitis B
Appraisal Guidance No 133 – Omalizumab for severe persistent allergic asthma
Appraisal Guidance No 137
NICE Single Technology Apprasial Guidance 140 and 141
Appraisal No 109: Docetaxel for the adjuvant treatment of early node-positive breast cancer
Appraisal Guidance No 119: Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia
Appraisal Guidance No 181 – Pemetrexed for the first-line treatment of non-small-cell lung cancer
Appraisal Guidance 126: Ritixumab for the treatment of rheumatoid arthritis
Appraisal Guidance 106 Peginterferon alfa and ribavarin for mild chronic hepatitis C
Appraisal Guidance 127: Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosi
Appraisal Guidance 123: Varenicline for smoking cessation
Appraisal Guidance No 116 Gemcitabine for the treatment of metastatic breast cancer
Appraisal Guidance No 112 Hormonal therapies for the adjuvant treatment early oestrogen-receptor-positive breast cancer

Evidence

Latest comments on NICE guidance released

27 February 2013

We released 2 comments:

NICE STA 274 Ranibizumab for the treatment of diabetic macular oedema (rapid review of TA237)
NICE STA guidance 275 Apixaban for preventing stroke and systemic embolism

NICE Guidance in development

Find the latest news on NICE guidance in development from the NICE website

Our on-going projects

Single Technology Appraisals

Contact us

Single Technology Appraisals in Scotland

Evidence

Latest comments on NICE guidance released